Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologyG Grazia, F. Schettini, Alessandra Gennari et al.|npj Breast Cancer|2026Cited by 6
357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)S. Nucera, Daniele Generali, F. Schettini et al.|Annals of Oncology|2024Cited by 0
347P Chemotherapy (CT) and GnRH analogue (a) benefit in patients (pts)≤50 years (y) with estrogen receptor-positive (ER+)/HER2-negative (-) stage I–II breast cancer (BC) risk-stratified by ProsignaF. Schettini, G Grazia, Vincenzo Di Lauro et al.|Annals of Oncology|2025Cited by 0